Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 23

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 23
---
 to:

| • | It is not possible to predict the actual number of Depositary Shares, if any, we will sell under the Purchase 
 Agreement, or the actual gross proceeds resulting from those sales or the dilution to you from those sales.   |

| • | Future resales and/or issuances of our Depositary Shares, including pursuant to this prospectus, or the 
 perception that such sales may occur, may cause the market price of our shares to drop significantly.   |

| • | We have incurred significant losses since our inception and anticipate that we will continue to incur 
 losses in the future.                                                                                 |

| • | Our requirement for additional financing in the short-term represents a material uncertainty that raises 
 substantial doubt about our ability to continue as a going concern.                                      |

| • | If we require or seek to raise additional capital to fund our operations and we fail to obtain necessary 
 financing, we may be unable to complete the development of our product candidates.                       |

| • | Our operations are in early-stage development with no sources of recurring revenue and there is no assurance 
 that we will successfully develop and license our product candidates or ever become profitable.              |

| • | We are exposed to political, regulatory, social and economic risk relating to the United Kingdom’s 
 exit from the European Union.                                                                      |

| • | We have undertaken in the past, and may in the future undertake, strategic acquisitions. Failure to integrate 
 acquisitions could adversely affect our value.                                                                |

| • | Our future success is dependent on product development and the ability to successfully license our product 
 candidates to partners who can seek regulatory approval and commercialization of our product candidates.   |

| • | Our development efforts are in the early stages. All of our product candidates are in clinical development                                  
 or preclinical development phases. If we are unable to advance our product candidates through clinical development, obtain regulatory       
 approval and ultimately commercialize our product candidates, or experience significant delays in doing so, our business will be materially 
 harmed.                                                                                                                                     |

| • | The results of preclinical studies and early clinical trials are not always predictive of future results.                               
 Any product candidate that we advance in clinical trials may not achieve favorable results in later clinical trials, if any, or receive 
 marketing approval.                                                                                                                     |

| • | The regulatory approval processes in the United States and Europe are lengthy, time consuming and inherently                               
 unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business may be substantially 
 harmed.